Thomas A. Fitzgerald - 28 Sep 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Chief Financial Officer, Director
Signature
/s/ Thomas A. Fitzgerald
Issuer symbol
RNAZ
Transactions as of
28 Sep 2023
Net transactions value
+$25,168
Form type
4
Filing time
02 Oct 2023, 16:39:08 UTC
Previous filing
19 May 2023
Next filing
18 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAZ Common Stock Purchase $25,168 +49,350 +708% $0.5100 56,318 28 Sep 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer.
F2 Reported amount reflects a 1-for-20 reverse stock split of the Issuer's common stock, which became effective as of May 22, 2023.